qCXL™ for Keratoconus
Keratoconus (corneal thinning disorder)
Pilot Clinical Study CompletedActive
Key Facts
Indication
Keratoconus (corneal thinning disorder)
Phase
Pilot Clinical Study Completed
Status
Active
Company
About TECLens
TECLens is a private, pre-revenue medical device startup developing a novel, non-invasive corneal cross-linking platform for vision correction. Its lead technology, qCXL™, aims to reshape the cornea using targeted UV light and real-time ultrasound monitoring, offering a potential alternative to invasive refractive surgeries and reading glasses for presbyopia. Founded in 2018 and based in San Diego, the company has attracted strategic investment from Johnson & Johnson and is building a pipeline targeting a broad range of refractive errors and corneal conditions.
View full company profile